Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"

The company is marketing the drug as a replacement to Roche Pharma’s Tocilizumab (originally approved for rheumatoid arthritis) that is currently in off label use (it means use of a drug for an unapproved indication) among Covid-19 patients who suffer from cytokine release syndrome (CRS) or “cytokine storm”.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2OnqQSd
via IFTTT